Written by

A lung cancer drug in testing by Eli Lilly and Co. performed well in a late-phase patient trial.

The Indianapolis drug maker said Wednesday that its experimental drug ramucirumab plus standard chemotherapy helped patients with non-small cell lung cancer live longer than patients who received just the standard chemotherapy.

Lilly said its scientists are pleased with the study results, which won't be released in detail until later this year. ...